Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice.
BACKGROUND
Hemophilia A is the most common serious bleeding disorder, and the hallmark of this disease is joint bleeding episodes. These result in hemophilic synovitis, an inflammatory and proliferative condition of the joint, which progresses into a chronic degenerative arthritis, hemophilic arthropathy.


METHODS
In this paper, we describe the effect of recombinant factor VIIa (rFVIIa), and an analogue NN1731 as well as rFVIII on needle-induced bleeding in hemophilia A mice.


CONCLUSIONS
Here we show a reducing effect of rFVIIa and NN1731 on bleeding induced in hemophilic mice, and we show that preventive treatment with rFVIII normalizes bleeding.
Ovlisen
K
K
Novo Nordisk A/S, Måløv, Denmark. saq@novonordisk.com
Kristensen
A T
AT
Valentino
L A
LA
Hakobyan
N
N
Ingerslev
J
J
Tranholm
M
M
D000818:Animals; D003029:Coagulants / Q000378:metabolism; D004195:Disease Models, Animal; D005167:Factor VII / Q000627:therapeutic use*; D005169:Factor VIII / Q000627:therapeutic use*; D015942:Factor VIIa / Q000627:therapeutic use*; D006395:Hemarthrosis / Q000473:pathology*; D006467:Hemophilia A / Q000235:genetics*; D006470:Hemorrhage / Q000188:drug therapy*; D006487:Hemostasis; D006801:Humans; D066298:In Vitro Techniques; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009339:Needles; D011994:Recombinant Proteins / Q000627:therapeutic use
D003029:Coagulants; C519901:NN1731; D011994:Recombinant Proteins; C078147:F8 protein, human; D005167:Factor VII; D005169:Factor VIII; C103587:recombinant FVIIa; D015942:Factor VIIa